In conclusion, after determining that the expression of TFRC in AML cells from AML patients did not significantly decrease after treatment with Ara-C, we generated Ara-C@HFn, which can be used to deliver Ara-C to AML cells specifically by recognizing TFRC that is expressed on AML cells at a high level. This evidence concerns the gene TFRC and acute myeloid leukemia.